Kiniksa Pharmaceuticals (KNSA)

• Market cap: $1.96B
• 1 day: 4.21%
• 5 days: 28.43%
• 1 month: 21.43%
• 3 months: 35.66%
• 6 months: 17.21%
• Year to date: 35.26%
• 1 year: 44.07%
• 5 years: 35.19%
• 10 years: 38.95%
• Sector: Healthcare
• Industry: Drug Manufacturers - Specialty & Generic

About: Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.

Employees: 315

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

3% more repeat investments, than reductions

Existing positions increased: 60 | Existing positions reduced: 58

1% less call options, than puts

Call options by funds: $2.39M | Put options by funds: $2.41M

3.76% less ownership

Funds ownership: 97.59% [Q3] → 93.83% (-3.76%) [Q4]

10% less funds holding

Funds holding: 175 [Q3] → 158 (-17) [Q4]

22% less capital invested

Capital invested by funds: $991M [Q3] → $772M (-$219M) [Q4]

44% less first-time investments, than exits

New positions opened: 19 | Existing positions closed: 34

67% less funds holding in top 10

Funds holding in top 10: 3 [Q3] → 1 (-2) [Q4]

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $34 26% upside
• Avg. target: $40 47% upside
• High target: $45 67% upside

3 analyst ratings

• positive: 3 100%
• neutral: 0 0%
• negative: 0 0%

Jefferies Roger Song 16% 1-year accuracy 3 / 19 met price target	67% upside $45	Buy Maintained	29 Apr 2025
Wedbush David Nierengarten 40% 1-year accuracy 46 / 114 met price target	26% upside $34	Outperform Reiterated	16 Apr 2025
Citigroup Geoff Meacham 45% 1-year accuracy 15 / 33 met price target	48% upside $40	Buy Initiated	13 Mar 2025